# Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

> **NCT06206512** · PHASE2 · COMPLETED · sponsor: **Sarfez Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Heart Failure
- Overactive Bladder
- Incontinence

## Interventions

- **DRUG:** Extended release torsemide
- **DRUG:** Immediate release torsemide
- **DRUG:** Extended release torsemide placebo
- **DRUG:** Immediate release torsemide placebo

## Key facts

- **NCT ID:** NCT06206512
- **Lead sponsor:** Sarfez Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-15
- **Primary completion:** 2025-11-17
- **Final completion:** 2026-03-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06206512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06206512, "Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06206512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*